Cephalon — Proxy Contest (April 2011)
32 slides from Cephalon's proxy contest presentation, Apr 11, 2011
Slide 1: Valeant's Offer to Acquire Cephalon
Valeant's Offer to Acquire Cephalon April 11, 2011
Slide 2: Forward-looking Statements
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"), including, but not limited to, statements regarding our offer to purchase Cephalon, Inc. ("Cephalon"), financ
Slide 3: Valeant's Offer and Cephalon's Standalone Risks
Valeant's Offer and Cephalon's Standalone Risks
Slide 4: Full Value and Certain Offer
Full Value and Certain Offer Offer delivers immediate and certain value to CEPH stockholders $73 per share all cash offer Maximize value now without risks associated with developing and commercializing pipeline Significant premium, opportunity for more Offer represents 29% premium to CEPH's 30-day t
Slide 5: VRX Believes Cephalon's Claims Are Unrealistic
VRX Believes Cephalon's Claims Are Unrealistic Cephalon's Claims Our Perspective VRX offer based on "worst case scenario" VRX considered all scenarios and based offer on public information CEPH pipeline has significant near- to mid-term commercial value and VRX offer ascribes little to no value to C
Slide 6: VRX's Offer Factors In Full Cephalon Story
VRX's Offer Factors In Full Cephalon Story CEPH's pipeline is risky and represents uncertain value Product revenues will be declining because of generic competition CEPH is not a high-growth biotechnology company VRX's offer represents full value and a fair premium
Slide 7: Pipeline Projects Often Do Not Result in Marketed Products
As Shown by Cephalon's Recent Struggles, Pipeline Projects Often do not Result in Marketed Products Treanda Nov-2008: Treanda approved for relapsed indolent non-Hodgkin's lymphoma Mar-2008: Treanda approved for chronic lymphocytic leukemia Treanda, which was Marketed in Germany Since the 1990's, is
Slide 8: CEPH Has Not Successfully Developed Any Major Novel Products Since 1998
CEPH has not Successfully Developed Any Major Novel Products Since 1998 Novel Products Since 1998 Novel Products Since 1998 Source: Evaluate Pharma; press releases History of acquiring primarily marketed products does not translate into successful biotech product development
Slide 9: Future Performance is Expected to be Down Significantly
Future Performance is Expected to be Down Significantly.... (CHART) (CHART) 2001-2010A Revenue CAGR: 30% 2011-2013E Revenue CAGR: (10%)* 2010A Operating Margin: 36% 2013E Operating Margin: 24%* Source: Red color denotes IBES Consensus Estimates, balance of data from CEPH filings * IBES Consensus Est
Slide 10: Earnings Performance is Expected to Decline Even More Rapidly Than Revenues
....Earnings Performance is Expected to Decline Even More Rapidly Than Revenues (CHART) Source: Red color denotes IBES Consensus Estimates, balance of data from CEPH filings * IBES Consensus Estimates as of 9-Apr-2011 (CHART) 2005-2010A EPS CAGR: 24% 2011-2013E EPS CAGR: (24%)*
Slide 11: Cephalon Not Expected to Perform Like a High-Growth Biotechnology Company
In Short, Cephalon is Not Expected to Perform Like a High-Growth Biotechnology Company Based on IBES consensus estimates: Revenues are expected to fall by 20% from 2011-2013 EPS is expected to fall by 42% from 2011-2013 Cephalon has not developed a major novel product since Provigil launched in the
Slide 12: Investors Do Not Value Cephalon Like a High-Growth Biotech Company
Investors Do Not Value Cephalon Like a High-Growth Biotech Company IBES Consensus EPS Growth Rate 2012 P / E Multiples Large Pharma Index 4.8% 9.5x Cephalon 5.0% 10.3x Specialty Pharma Peers 10.8% 10.9x High-Growth Biotech Index 38.4% 32.5x Share price as of close 29-Mar-2011, prior to VRX offer bec
Slide 13: Unaffected Cephalon Share Price Reflects Actual Decline in Fundamental Value
Unaffected Cephalon Share Price Reflects Actual Decline in Fundamental Value Declines reflect significant pipeline failures and loss of value to stockholders 52-week high occurred after sale rumors began Source: Capital IQ and CEPH press releases (CHART)
Slide 14: VRX Offer at a 29% Premium is Fair
VRX Offer at a 29% Premium is Fair 25% is the median U.S. acquisition premium to 30-day trading averages since 2006 - our offer represents a 29% premium 24% median premium to 1 day trading price Substantial value leakage due to change of control costs on CEPH's convertible bond and call spread Since
Slide 15: Analysts Support Valeant's Offer
Analysts Support Valeant's Offer "Despite our assertion that the market is well aware that Cephalon earnings will decline, we do not argue the stock have reached a floor. ...while the pipeline lottery cards are keeping us away from suggesting shorting the stock, they are not nearly robust enough to
Slide 16: Valeant's Written Consent Solicitation
Valeant's Written Consent Solicitation
Slide 17: Timing is Critical for VRX
Timing is Critical for VRX VRX believes CEPH has unsustainable set of assets, earnings and cash flow Near term patent cliffs and generic competition VRX believes a substantial amount of CEPH's equity value is represented by cash flows in the next 12 months Every day of delay in implementing our busi
Slide 18: Consent Solicitation Timeline and Next Steps
Consent Solicitation Timeline and Next Steps Record Date: April 8, 2011 Expect to mail consent solicitation materials week of April 18 VRX's deadline is May 12, 2011 to receive requisite consents If we have a majority, we will seat our slate; if not, we will move on New Board could be seated immedia
Slide 19: Highly Qualified Group of Independent Nominees
Highly Qualified Group of Independent Nominees Exceptional slate of highly qualified and well-respected professionals Right combination of skills and experience to effectively govern CEPH Extensive expertise in the healthcare and pharmaceuticals industries, including R&D Strong Management and Corpor
Slide 20: Valeant's Nominees
Valeant's Nominees Name Healthcare/ Pharma Corp Governance Management Finance Legal Santo J. CostaFormer President and COO of Quintiles Richard H. Koppes Former General Counsel and Interim CEO of CalPERS Lawrence N. Kugelman Former CEO and President of Coventry Health Care Anders Lonner Group Presid
Slide 21: Our Board Slate Is Experienced in Evaluating the Key Aspects of the Offer
Our Board Slate Is Experienced in Evaluating the Key Aspects of the Offer Pipeline Evaluation Santo Costa (former CEO of Quintiles, Adjunct Professor in Clinical Research, Director of the Food and Drug Institute Advisory Board) Anders Lonner (CEO of Meda AB, winner of the 2008 Arthur D. Little Nordi
Slide 22: Cephalon's Board Has Not Delivered Value to Stockholders
Cephalon's Board Has Not Delivered Value to Stockholders Stockholders have lost value over the last 5 years Track record of pipeline failures Have been unable to find a solution to impending patent cliff Incentives not aligned with stockholders Board and management in aggregate only own 0.25% of bas
Slide 23: CEPH Stockholders Will Decide by May 12th
CEPH Stockholders Will Decide by May 12th The choice is clear: Certain $73 in cash (or more if diligence warrants an increased price) versus uncertain standalone strategy CEPH's Board and management have rejected our efforts to negotiate a transaction that would deliver immediate and certain value I
Slide 24: Appendix A
Appendix A Wy VALEANT
Slide 25: Valeant Pharmaceuticals Overview
Valeant Pharmaceuticals Overview Focused, multinational specialty pharma company Specialty Pharma (U.S., Canada, Australia, New Zealand) Dermatology, Neurology and Other Branded Generics - Central Europe (Poland, Serbia, Hungary, Czech Republic) Branded Generics - Latin America (Mexico, Brazil) Dive
Slide 26: Strategic Rationale
Strategic Rationale Transaction consistent with Valeant strategy Significant opportunities Maximize organic growth and cash flow of in-line specialty pharmaceutical products Enhance European branded generic business Apply Valeant Leveraged R&D model to Cephalon pipeline Provigil cash flows and poten
Slide 27: Strong Execution Track Record
Strong Execution Track Record SOURCE: Valeant Valeant Management Team Performance** USD 740% price adjusted increase in companies under current management team (Feb 2008 to today) Consistently exceeded quarterly expectations Total returned to stockholders via repurchases: $850M (shares @ $12.42 aver
Slide 28: Management's Successful M&A Track Record
Management's Successful M&A Track Record Aton Pharma Biovail/Valeant Merger Blaufarma Bunker Cholestagel Coria Labs Delta DermaTech Dow Pharmaceutical Sciences EMO-FARM Hamilton Suncare Laboratories Dr. Renaud PharmaSwiss Private Formula International Reckitt Benckiser (Australia Suncare Products) R
Slide 29: Appendix B
Appendix B Wy VALEANT
Slide 30: Nominee Biographies
Nominee Biographies Mr. Santo J. Costa. Mr. Costa is Chairman of the Board of Labopharm Inc. and is currently Of Counsel with Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P., of Raleigh, North Carolina, specializing in corporate law for healthcare companies. Mr. Costa currently serve
Slide 31: Nominee Biographies
Nominee Biographies Dr. John H. McArthur. Dr. McArthur was Dean of the Faculty of Harvard Business School from 1980 through 1995. Since then, he has held the positions of Professor of Business Administration Emeritus and Dean Emeritus. He was a member of the School's faculty from 1962, where he taug
Slide 32: Valeant's Offer to Acquire Cephalon
Valeant's Offer to Acquire Cephalon April 11, 2011